VLG vs. ARIX, BVXP, TSTL, FARN, AVCT, BXP, 4BB, ANCR, CIR, and HVO
Should you be buying Venture Life Group stock or one of its competitors? The main competitors of Venture Life Group include Arix Bioscience (ARIX), Bioventix (BVXP), Tristel (TSTL), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), Beximco Pharmaceuticals (BXP), 4basebio (4BB), Animalcare Group (ANCR), Circassia Group (CIR), and hVIVO (HVO). These companies are all part of the "medical" sector.
Venture Life Group vs.
Venture Life Group (LON:VLG) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
69.5% of Venture Life Group shares are held by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are held by institutional investors. 10.4% of Venture Life Group shares are held by company insiders. Comparatively, 20.7% of Arix Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Arix Bioscience has lower revenue, but higher earnings than Venture Life Group. Arix Bioscience is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.
Venture Life Group has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Venture Life Group received 74 more outperform votes than Arix Bioscience when rated by MarketBeat users. Likewise, 72.90% of users gave Venture Life Group an outperform vote while only 63.57% of users gave Arix Bioscience an outperform vote.
Arix Bioscience has a net margin of 105.64% compared to Venture Life Group's net margin of 1.44%. Arix Bioscience's return on equity of 6.41% beat Venture Life Group's return on equity.
In the previous week, Venture Life Group had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Venture Life Group and 0 mentions for Arix Bioscience. Venture Life Group's average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.
Summary
Arix Bioscience beats Venture Life Group on 8 of the 14 factors compared between the two stocks.
Get Venture Life Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Venture Life Group Competitors List
Related Companies and Tools
This page (LON:VLG) was last updated on 12/18/2024 by MarketBeat.com Staff
Free VLG Stock Alerts